Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Conditions:   Advanced Cancer;   Anal Carcinoma;   Anal Cancer;   Biliary Cancer;   Cholangiocarcinoma;   Bile Duct Cancer;   Neuroendocrine Tumor;   Carcinoid Tumor;   Endometrial Carcinoma;   Endometrial Cancer;   Cervical Carcinoma;   Cervical Cancer;   Vulvar Carcinoma;   Vulvar Cancer;   Small Cell Lung Carcinoma;   Small Cell Lung Cancer (SCLC);   Mesothelioma;   Thyroid Carcinoma;   Thyroid Cancer;   Salivary Gland Carcinoma;   Salivary Gland Cancer;   Salivary Cancer;   Parotid Gland Cancer;   Advanced Solid Tumors;   Colorectal Carcinoma
Intervention:   Biological: pembrolizumab
Sponsor:   Merck Sharp & Dohme LLC

Source: View full study details on

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 15, 2022Comments | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine